文献速递淋巴瘤

伊布替尼联合维奈克拉一线治疗慢性淋巴细胞白血病:CAPTIVATE研究MRD队列主要分析

Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
PubMed 文献 · J Clin Oncol · 2021-10-07

CAPTIVATE随机II期研究评估初治CLL患者接受伊布替尼联合维奈克拉后基于MRD指导停药。提示该全口服无化疗方案可能实现固定疗程治疗。

要点

  • 伊布替尼联合维奈克拉后最佳uMRD率:外周血75%,骨髓68%。
  • 确认uMRD患者中安慰剂组1年DFS率95%,伊布替尼组100%,差异无统计学意义。
  • 基线高肿瘤溶解综合征风险患者中90%(36/40)经伊布替尼前导后降为中或低风险。

核心结论

  • 确认uMRD患者安慰剂组1年DFS率95%,提示该全口服无化疗方案可能实现固定疗程治疗。

研究设计与样本

  • 随机II期CAPTIVATE研究(NCT02910583),初治CLL患者年龄<70岁。
  • 患者先接受3周期伊布替尼,再接受12周期伊布替尼联合维奈克拉。
  • 确认uMRD者随机1:1双盲接受安慰剂或伊布替尼;未确认uMRD者随机1:1接受伊布替尼或伊布替尼联合维奈克拉。

主要发现

  • 伊布替尼联合维奈克拉12周期后,最佳uMRD率外周血75%、骨髓68%。
  • 确认uMRD患者随机接受安慰剂(n=43)或伊布替尼(n=43);未确认uMRD者随机接受伊布替尼(n=31)或伊布替尼联合维奈克拉(n=32)。
  • 基线高肿瘤溶解综合征风险40例中36例(90%)经伊布替尼前导肿瘤减负后转为中或低风险。

关键数值与推荐

  • 主要终点为确认uMRD人群中安慰剂对比伊布替尼的1年DFS率。
  • 次要终点包括缓解率、uMRD和安全性。
  • 不良事件最常见于伊布替尼联合维奈克拉治疗前6个月,随后总体减少。

临床怎么用

  • 初治CLL可采用伊布替尼前导后联合维奈克拉的全口服无化疗方案。
  • 确认uMRD后可考虑停药观察,1年DFS率与继续伊布替尼无显著差异。
  • 伊布替尼前导可降低高肿瘤溶解综合征风险患者的风险等级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leukemia (CLL). METHODS: Previously untreated CLL patients age < 70 years received three cycles of ibrutinib and then 12 cycles of combined ibrutinib plus venetoclax. Patients in the MRD cohort who met the stringent random assignment criteria for confirmed undetectable MRD (Confirmed uMRD) were randomly assigned 1:1 to double-blind placebo or ibrutinib; patients without Confirmed uMRD (uMRD Not Confirmed) were randomly assigned 1:1 to open-label ibrutinib or ibrutinib plus venetoclax. Primary end point was 1-year disease-free survival (DFS) rate with placebo versus ibrutinib in the Confirmed uMRD population. Secondary end points included response rates, uMRD, and safety. RESULTS: One hundred sixty-four patients initiated three cycles of ibrutinib lead-in. After 12 cycles of ibrutinib plus venetoclax, best uMRD response rates were 75% (peripheral blood) and 68% (bone marrow). Patients with Confirmed uMRD were randomly assigned to receive placebo (n = 43) or ibrutinib (n = 43); patients with uMRD Not Confirmed were randomly assigned to ibrutinib (n = 31) or ibrutinib plus venetoclax (n = 32). Median follow-up was 31.3 months. One-year DFS rate was not significantly different between placebo (95%) and ibrutinib (100%; arm difference: 4.7% [95% CI, -1.6 to 10.9]; P = .15) in the Confirmed uMRD population. After ibrutinib lead-in tumor debulking, 36 of 40 patients (90%) with high tumor lysis syndrome risk at baseline shifted to medium or low tumor lysis syndrome risk categories. Adverse events were most frequent during the first 6 months of ibrutinib plus venetoclax and generally decreased over time. CONCLUSION: The 1-year DFS rate of 95% in placebo-randomly assigned patients with Confirmed uMRD suggests the potential for fixed-duration treatment with this all-oral, once-daily, chemotherapy-free regimen in first-line CLL.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Wierda WG, Allan JN, Siddiqi T, et al. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. J Clin Oncol. 2021. PMID: 34618601. doi:10.1200/JCO.21.00807

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。